U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07342179) titled 'CAR-T Immunomonitoring in Multiple Myeloma (CART I5M)' on Dec. 01, 2025.
Brief Summary: Multiple myeloma patients can be treated with cell therapy, which uses some of their own modified white blood cells (T lymphocytes) to target a protein (BCMA, or B-cell maturation antigen) found on the surface of the myeloma plasma cells. These modified T lymphocytes are called CAR T cells (chimeric antigen receptor T cells). The long-term persistence of these modified lymphocytes, or CAR-BCMA, is a recognized indicator of a good response to treatment. This research aims to study certain markers related to CAR-BCMA cell persistence. This research...